🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 6 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/01/2014 26,80 26,90 25,49 25,71 -4,95% 5,26% 285.600
28/01/2014 27,01 27,67 26,62 27,05 +0,52% 3,89% 482.100
27/01/2014 26,63 27,75 26,16 26,91 +0,04% 5,97% 274.400
24/01/2014 21,85 27,67 21,75 26,90 +2,59% 27,09% 1.078.300
23/01/2014 26,70 27,01 25,21 26,22 -2,31% 6,74% 257.700
22/01/2014 28,73 28,82 26,76 26,84 -7,32% 7,17% 546.000
21/01/2014 29,32 30,40 28,54 28,96 -1,23% 6,34% 432.400
17/01/2014 26,50 30,00 26,50 29,32 +10,43% 13,21% 481.800
16/01/2014 25,00 27,65 24,43 26,55 +7,75% 12,88% 783.000
15/01/2014 21,96 24,99 21,77 24,64 +12,67% 14,66% 437.800
14/01/2014 19,89 21,96 19,87 21,87 +10,07% 10,51% 212.500
13/01/2014 19,75 20,79 19,30 19,87 +1,90% 7,54% 176.300
10/01/2014 18,00 20,22 17,93 19,50 +8,09% 12,72% 149.200
09/01/2014 17,99 18,27 17,78 18,04 +1,63% 2,72% 79.600
08/01/2014 16,85 17,84 16,85 17,75 +6,22% 5,88% 110.500
07/01/2014 16,78 17,09 16,25 16,71 -0,06% 5,01% 59.400
06/01/2014 17,54 17,72 16,47 16,72 -4,18% 7,13% 27.500
03/01/2014 16,76 17,51 16,21 17,45 +4,24% 7,76% 67.200
02/01/2014 16,73 17,18 16,32 16,74 -1,36% 5,14% 101.100
31/12/2013 17,50 17,58 16,93 16,97 -3,03% 3,71% 124.600
30/12/2013 17,99 17,99 17,44 17,50 -1,69% 3,06% 45.600
27/12/2013 18,30 18,30 17,62 17,80 -2,79% 3,72% 75.700
26/12/2013 19,00 19,20 17,77 18,31 -4,14% 7,53% 103.800
24/12/2013 18,20 19,20 17,90 19,10 +3,75% 7,14% 87.200
23/12/2013 18,83 18,83 17,64 18,41 -2,28% 6,32% 200.000
20/12/2013 18,75 19,12 18,05 18,84 +0,37% 5,71% 780.600
19/12/2013 18,93 18,97 18,46 18,77 -1,21% 2,69% 77.200
18/12/2013 19,22 19,30 18,69 19,00 -0,78% 3,17% 181.200
17/12/2013 19,30 19,72 18,61 19,15 -0,98% 5,75% 325.400
16/12/2013 17,07 19,57 16,95 19,34 +13,90% 15,35% 540.300